Linagliptin
- Generic Name
- Linagliptin
- Brand Names
- Glyxambi, Jentadueto, Tradjenta, Trajenta, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C25H28N8O2
- CAS Number
- 668270-12-0
- Unique Ingredient Identifier
- 3X29ZEJ4R2
- Background
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
- Indication
Linagliptin is indicated for the treatment of type II diabetes in addition to diet and exercise. It should not be used to treat type I diabetes or in diabetic ketoacidosis. An extended-release combination product containing empagliflozin, linagliptin, and metformin was approved by the FDA in January 2020 for the improvement of glycemic control in adults with...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Linagliptin Add-on to Insulin Background Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 206
- Registration Number
- NCT02897349
- Locations
- 🇨🇳
Tianjin Medical University General Hospital, Tianjin, China
🇨🇳The General Hospital of Chinese People's Armed Police Forces, Beijing, China
🇨🇳Shengjing Hospital of China Medical University, Shengyang, China
Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry
- Conditions
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Heart Care Foundation
- Target Recruit Count
- 188
- Registration Number
- NCT02851745
- Locations
- 🇮🇹
Ospedale Sandro Pertini, Roma, RM, Italy
🇮🇹Ospedale Casa Sollievo Della Sofferenza, San Giovanni Rotondo, FG, Italy
🇮🇹Iclas-Istituto Clinico Ligure Alta Spec., Rapallo, GE, Italy
The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2016-06-07
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 24
- Registration Number
- NCT02792400
- Locations
- 🇩🇰
Center for Diabetes Research, Gentofte Hospital, Copenhagen University, Hellerup, Denmark
The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2018-02-15
- Lead Sponsor
- Northwell Health
- Registration Number
- NCT02768220
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 56
- Registration Number
- NCT02758171
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Incretin Axis in Type 1 Diabetes Mellitus
- First Posted Date
- 2016-04-01
- Last Posted Date
- 2016-04-01
- Target Recruit Count
- 20
- Registration Number
- NCT02725502
- Locations
- 🇮🇳
Department of Endocrinology, PGIMER, Chandigarh, India
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
- Conditions
- Interventions
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2018-10-12
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT02608177
- Locations
- 🇺🇸
University of Washington, Seattle, Washington, United States
Linagliptin's Effect on CD34+ Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2023-01-19
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 31
- Registration Number
- NCT02467478
- Locations
- 🇺🇸
The George Washington University Medical Faculty Associates, Washington, District of Columbia, United States
Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 275
- Registration Number
- NCT02453555
- Locations
- 🇯🇵
Fukuwa Clinic, Tokyo, Chuo-ku, Japan
🇯🇵Nakakinen Clinic, Ibaraki, Naka, Japan
🇯🇵Hiraoka Naika Clinic, Hiroshima, I.M., Hiroshima, Hiroshima, Japan
Linagliptin and Mesenchymal Stem Cells: A Pilot Study
- First Posted Date
- 2015-05-13
- Last Posted Date
- 2020-11-09
- Lead Sponsor
- University of Nevada, Reno
- Target Recruit Count
- 10
- Registration Number
- NCT02442817
- Locations
- 🇺🇸
University of Nevada School of Medicine, Reno, Nevada, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.